Healthcare / Drug Manufacturers - GeneralNSE
$512.25
+1.15 (+0.24%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 14%
FCF escenarios
weak_data · normalized FCF $-301.4M · quality 30.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
12/100
SEC 0%
Sin guardar todavía.
Market Cap
$22.6B
P/E
115.9x
↑EV/EBITDA
45.2x
↑ROE
17.6%
↑Gross Margin
45.4%
↓Debt/Equity
1.83
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2025 · 2 años de histórico normalizado
Revenue CAGR
+126.1%
FCF CAGR
—
FCF margin
6.6%
FCF / Net income
1.66x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.95B · net income $196.3M · FCF $326.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | $4.95B | $4.95B | $1.54B | $968.0M |
| Net Income | $196.3M | $196.3M | $84.2M | $43.8M |
| EBITDA | $543.5M | $543.5M | $331.0M | $187.7M |
| EPS | 4.44 | 4.44 | 1.90 | 0.99 |
| Gross Margin | 45.4% | 45.4% | 38.2% | 40.1% |
| Operating Margin | 6.4% | 6.4% | 16.7% | 17.3% |
| Net Margin | 4.0% | 4.0% | 5.5% | 4.5% |
| Balance Sheet | ||||
| Debt/Equity | 1.83 | 1.83 | 1.59 | 2.18 |
| Current Ratio | 1.44 | 1.44 | — | — |
| Cash Flow | ||||
| Free Cash Flow | $326.5M | $326.5M | $-738.6M | $-301.4M |
| Returns | ||||
| ROE | 17.6% | 17.6% | 11.3% | 13.9% |
| Valuation | ||||
| P/E | 115.89 | 115.89 | — | — |
| EV/EBITDA | 45.24 | 45.24 | — | — |
| P/B | 20.30 | 20.30 | — | — |
| Growth & Yield | ||||
| Revenue Growth | 221.9% | 221.9% | 58.9% | — |
| EPS Growth | 133.3% | 133.3% | 92.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
117.1%
EPS terminal req.
$45.45
Spread vs growth
16.2%
5Y implied EPS CAGR
65.4%
EPS terminal req.
$55.00
Spread vs growth
67.9%
10Y implied EPS CAGR
34.9%
EPS terminal req.
$88.58
Spread vs growth
98.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.8%
Start / end P/E
213.0x → 109.4x
EPS bridge
1.90 → 4.44
Residual
-64.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.